世界の生物製剤医薬品受託製造開発機関企業 (CDMO) 市場予測：2022年
Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022
|発行||Frost & Sullivan||商品コード||712901|
|出版日||ページ情報||英文 93 Pages
|世界の生物製剤医薬品受託製造開発機関企業 (CDMO) 市場予測：2022年 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022|
|出版日: 2018年09月19日||ページ情報: 英文 93 Pages||
当レポートでは、世界における生物製剤医薬品受託製造開発機関企業 (CDMO) の状況について、世界の生物製剤アウトソーシング市場における主な動向と成長機会に注目して分析しており、市場の成長展望と成長率、急成長セグメント、成長機会、主な成長促進要因・抑制要因、主な課題、革新的企業などについてまとめています。
Investments in Single Use/Disposable Technologies to Capitalize on Growth Opportunities in High-value Low-volume Biologics
The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global biologics Contract Development and Manufacturing Organization (CDMO) landscape with an emphasis on the key trends and growth opportunities across the global biologics outsourcing market. It also highlights the shifting focus and investments of pharma/biotech participants toward BioCDMOs for innovative biologics discovery, development, and manufacturing.
With the changing market landscape, BioCDMOs are shifting toward providing value-added services by establishing themselves as a one-stop-shop for their pharma clients. These companies are adopting advanced manufacturing technologies such as single-use/disposable bioreactors, continuous, POD manufacturing, and so on with the integration of IT-based solutions implementing the Industrial Internet of Things (IIoT) by means of strategic collaborations and partnerships. Larger participants are resorting to Mergers and Acquisitions (M&As) in order to gain specific therapeutic and technical expertise from smaller, niche BioCDMOs. While the US and Europe are key markets, the outsourcing trend is slowly shifting toward APAC with several new entrants providing cost-effective drug development services.
The study aims at identifying some key growth opportunities such as biosimilars co-development, designer cell lines, bioanalytical development and services, and so on that are set to drive the market over the next 5 years. It provides revenue forecasts of the global BioCDMO market as well as a breakdown by type of cell culture (mammalian versus microbial) and service type (drug substance verus drug product). The study highlights some of the key market drivers and restraints that will affect the overall growth of the market. Additionally, it provides an insight into leading disruptive technology trends such as improvements in upstream and downstream technologies, advances in lyophilisation, and increased application of Process Analytical Technologies (PAT) that are shaping the future of the BioCDMO industry. The study also highlights some emerging business models such as expanding services of CMOs into early stage of drugs, emergence of virtual biotech, out-licensing, and risk sharing between pharma and CMOs that are disrupting traditional business models.